Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Narsoplimab for adult TA-TMA

Sergio A. Giralt, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, explores the use of narsoplimab, an investigational MASP-2 inhibitor, currently evaluated for the treatment of adult transplant-associated thrombotic microangiopathy (TA-TMA). Recent studies have highlighted the efficacy of narsoplimab against TA-TMA, and Prof. Giralt discusses the promise of this agent. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.